Skip to main content

Table 3 Summary of primary and secondary outcomes, process measures, mediating factors and required sample sizes for each cancer

From: Reorganising specialist cancer surgery for the twenty-first century: a mixed methods evaluation (RESPECT-21)

Prostate cancer

Primary outcome

• Radical prostatectomy: proportion of men treated by primary surgery who remain continent (pad free) at 12 months (research indicates range of 80–92%, depending on procedure) [69]

Secondary outcomes

• Radical prostatectomy: proportion of men treated by surgery with pre-operative erectile function who have erections sufficient for penetration at 12 months

• Length of stay

• Readmission

• Surgical complications

• Post-operative complications

• Diagnostic outcomes: proportion of men diagnosed with clinically significant prostate cancer

• Patient experience, including choice of treatment, access to services, confidence in staff, communication, effectiveness of teamwork and opportunity to participate in research

Bladder cancer

Primary outcome

• 30-day post-operative mortality (national figure (2012) = 2.4%) [70]

Secondary outcomes

• Length of stay

• Proportion of patients offered neo-bladder reconstruction

• Proportion of patients receiving neo-bladder reconstruction

• Surgical complications (measured by Clavien–Dindo grading)

• Patient experience (measures as above)

Renal cancer

Primary outcome

• 30-day post-operative mortality (anticipated figure = 0.9%) [71]

Secondary outcomes

• 30 day readmission

• % of cases of T1a tumours having nephron-sparing surgery

• Length of stay

• Surgical complications (measured by Clavien–Dindo grading)

• Conversion from laparoscopic (including robotically assisted) to open surgery

• Patient experience (measures as above)

OG cancer

Primary outcome

• 30-day post-operative mortality (national figure (2013) = 2.3%) [72]

Secondary outcomes

• % of patients offered endoscopic resection for tumours staged as T1a

• Length of stay

• % Complete R0 resection (i.e. full removal of tumour)

• Surgical complications—anastomotic leak

• Patient experience (measures as above)

Intermediate outcomes (all)

 

• Waiting times (within 62 days of referral, 31 days of decision to treat)

• Number of patients seen by surgeon

• Case volume per surgeon

• Proportion of cases where surgery is an emergency procedure

Mediating factors (all)

 

• Patient characteristics (age, gender, ethnicity, socioeconomic status)

• Cancer stage

• Whether procedure is a salvage procedure